Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | CARTISTEM? | Company | MEDIPOST Co., Ltd. |
|---|---|---|---|
| Classification | Cell Therapy product | Active Ingredient | Human Umbilical Cord Blood-derived Mesenchymal Stem Cells, 7.5x106 cells/vial |
| Reference Product | Approval Date | 2012 | |
| Indication | Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma | ||
| Description |
CARTISTEM?is a drug based on allogeneic umbilical cord blood derived mesenchymal stem cells. It is indicated to treat knee cartilage defects as a result of degenerative osteoarthritis or repeated trauma. CARTISTEM? is administered to through either a surgical method or an arthroscope.
|
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.